Table 4.
Mirikizumab effect on genes correlated with stool frequency or bowel urgency
| Genes correlated with stool frequencya | Baseline vs week 12 200 mg mirikizumabb |
| 212 (+) | 212 ↓ |
| 55 (−) | 55 ↑ |
| Genes correlated with bowel urgencya | Baseline vs week 12 200 mg mirikizumabb |
| 296 (+) | 296 ↓ |
| 24 (−) | 24 ↑ |
| Genes correlated with both stool frequency and bowel urgency | Baseline vs week 12 200 mg mirikizumab |
| 107 (+) | 107 ↓ |
| 15 (−) | 15 ↑ |
For stool frequency, 212 genes were positively correlated (increased gene expression and greater stool frequency) and 55 negatively correlated (increased gene expression and lesser stool frequency). For bowel urgency, 296 genes were positively correlated and 24 negatively correlated. One hundred seven genes were positively correlated with both stool frequency and bowel urgency while 15 genes were negatively correlated with both.
Number of genes correlated with stool frequency or bowel urgency: |tau| >0.3 and q-value <0.001. For stool frequency (baseline N = 224, week 12 N = 219), |tau| >0.225 and q-value <0.001; for bowel urgency (baseline N = 223, week 12 N = 219). All patients included in the analysis had both gene expression and stool frequency or bowel urgency data at the given time point.
The effect of mirikizumab treatment on these genes are indicated with arrows. N = 53 patients in the mirikizumab 200 mg IV dose group who had biopsies at both baseline and week 12.